Vifor Pharma Group Announces Successful Sale of OM Pharma
18.9.2020 08:00:00 EEST | Business Wire | Press release
Regulatory News:
Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include:
- A purchase consideration of MCHF 435 for 100% of the share capital
- An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple
This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days.
OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years.
Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries and exporting to 60 countries worldwide, as a strategic partner. Optimus Holding is fully committed to the sustainable growth of OM Pharma and to invest considerably in R&D to become a global biotechnology company focused on improving the lives of patients with respiratory and inflammatory diseases.
Stefan Schulze, CEO of Vifor Pharma Group comments, “I am very pleased to have successfully completed the competitive sale process of OM Pharma announced earlier this year that was overseen by Rothschild & Co. Optimus Holding Ltd. brings a wealth of expertise and OM Pharma will benefit from the knowledge, financial investment and operational synergies of the new owners. This sale strengthens our strategic focus and will enable the company to further invest into our exciting product pipeline, especially in our core therapeutic area of nephrology.”
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005959/en/
Contact information
Vifor Pharma Group:
Media Relations
Nathalie Ponnier
Global Head of Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
Optimus Holding Ltd.:
Beatrix Benz
+41 79 256 77 73
beatrix.benz@benz-advisory.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Study: As AI Drives a Summer Travel Boom, Clunky Security and Scam Fears Threaten Merchant Conversions30.6.2026 15:30:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released findings from global survey conducted ahead of the 2026 Summer Travel season, exploring consumer travel behavior, booking experiences, and trust in digital and AI-enabled travel tools. The survey, conducted among more than 4,000 consumers across the United States, United Kingdom, China, Japan, Mexico, Brazil, and Colombia, shows strong demand for travel heading into the summer season, alongside continued adoption of digital and AI tools in trip planning. Key findings from the Riskified 2026 Summer Travel Survey include: 81% of consumers use digital platforms for travel planning, with 26% already relying on AI like ChatGPT or Gemini. Leisure remains the dominant purpose of travel at 63%, followed by visiting friends and family (25%), going to live events (7%), and business travel (5%). 47% cite payment security and 39% cite fake or invalid tickets as top concerns when buying tickets online.
Corpay Cross-Border Named the Official Global FX Partner of Fever30.6.2026 15:30:00 EEST | Press release
Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, today announced that its Cross-Border business has entered into an agreement with Fever, a leading global live-entertainment discovery and ticketing platform that specializes in immersive experiences, candlelit concerts, and interactive pop-up events. Under the agreement, Corpay becomes Fever’s exclusive and Official Global Foreign Exchange (FX) Partner. Through this partnership, Fever’s global operations across North America, Mexico, the UK, EMEA, and APAC will be able to leverage Corpay Cross-Border’s innovative solutions to help manage foreign exchange exposure arising from day-to-day business activities. “Fever represents the future of global live entertainment and event ticketing technology, and we are honoured to be named their exclusive and Official FX Partner,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership reinforces our position as the leading provider of corporate p
Allegro DVT Plays a Pivotal Role in Groundbreaking CHASSIS Automotive Base Die Development30.6.2026 15:15:00 EEST | Press release
Allegro DVT announced its contribution to the European CHASSIS program's implementation of the Automotive Base Die chiplet. The 5nm chiplet is set to revolutionize the automotive semiconductor landscape, laying the foundation for the open and standardized chiplet ecosystem that will enable the next generation of software-defined vehicles. The Automotive Base Die acts as the central communication and integration hub for automotive System-on-Chip (SoC) infrastructure, which is designed to enable seamless integration of third-party chiplets via the Universal Chiplet Interconnect Express (UCIe) standard. The Automotive Base Die is funded within the Chips JU program CHASSIS by leading European entities BMW, imec, and Bosch, which aims to enable unprecedented flexibility and innovation in the automotive industry. Allegro DVT’s expertise has been instrumental in the development of this foundational technology. Specifically, Allegro DVT has provided its Encoding and Decoding Semiconductor Vide
SLB Awarded Seven-Year Contract Under Kuwait Oil Company's Ahmadi Innovation Valley Initiative30.6.2026 15:06:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) has been awarded a seven-year contract by Kuwait Oil Company (KOC) under the Ahmadi Innovation Valley (AIV) initiative. The agreement will support applied research, technology deployment and digital innovation programs aligned with Kuwait's long-term energy objectives. Under the agreement, SLB will work with KOC to evaluate, test and deploy advanced technologies across a range of operational and strategic priorities, including artificial intelligence (AI), industrial internet of things (IIoT) applications, production optimization, reservoir technologies, water management and energy transition initiatives. Ahmadi Innovation Valley is KOC's flagship innovation initiative that brings together industry, academia and technology providers to address strategic upstream technical challenges. "Ahmadi Innovation Valley represents an important step in advancing technology leadership across Kuwait's energy sector," said Ahmad Jaber Al-Eidan, chief e
IFF Launches SENSORA™, an Innovative Pro-Fragrance Technology Platform30.6.2026 15:00:00 EEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health and biosciences — today announced the launch of SENSORA™, its advanced patent-pending pro-fragrance technology designed to transform how scent is experienced across home, fabric and personal care applications. Developed to meet the rising demand for a longer-lasting and more sophisticated scent experience, SENSORA™ delivers an evolving olfactive profile with sustained release, extending enjoyment well beyond first use. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629247253/en/ SENSORA™, IFF’s light-activated pro-fragrance experience enhancer “With SENSORA™, we are advancing fragrance performance into a new territory — one where scent continues to reveal itself in real life, long after the first moment of use,” said Ana Paula Mendonça, president of IFF Scent. “By combining pro-fragrance science with our deep expertise in fragrance desig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom